Advanced search
Publication Cover
Scandinavian Journal of Gastroenterology Volume 59, 2024 - Issue 6
Submit an article Journal homepage
551
Views
1
CrossRef citations to date
0
Altmetric
Brief Report

Activin A levels in metabolic dysfunction-associated steatotic liver disease associates with fibrosis and the PNPLA3 I148M variant

Cecilia Jönssona Division of Diagnostics and Specialist Medicine, Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, SwedenCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-0981-0264View further author information
ORCID Icon,
Martin Bergramb Division of Prevention, Rehabilitation and Community Medicine, Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, SwedenORCID Iconhttps://orcid.org/0000-0001-8524-1900View further author information
ORCID Icon,
Stergios Kechagiasa Division of Diagnostics and Specialist Medicine, Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, SwedenORCID Iconhttps://orcid.org/0000-0001-7614-739XView further author information
ORCID Icon,
Patrik Nasra Division of Diagnostics and Specialist Medicine, Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden;c Wallenberg Centre for Molecular Medicine, Linköping University, Linköping, SwedenORCID Iconhttps://orcid.org/0000-0002-2928-4188View further author information
ORCID Icon &
Mattias Ekstedta Division of Diagnostics and Specialist Medicine, Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, SwedenORCID Iconhttps://orcid.org/0000-0002-5590-8601View further author information
ORCID Icon
Pages 737-741 | Received 17 Jan 2024, Accepted 20 Mar 2024, Published online: 02 Apr 2024

References

  • Riazi K, Azhari H, Charette JH, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7(9):851–861. doi: 10.1016/S2468-1253(22)00165-0.
  • Kechagias S, Nasr P, Blomdahl J, et al. Established and emerging factors affecting the progression of nonalcoholic fatty liver disease. Metabolism. 2020;111S:154183. doi: 10.1016/j.metabol.2020.154183.
  • Date M, Matsuzaki K, Matsushita M, et al. Differential regulation of activin A for hepatocyte growth and fibronectin synthesis in rat liver injury. J Hepatol. 2000;32(2):251–260. doi: 10.1016/s0168-8278(00)80070-7.
  • Wada W, Kuwano H, Hasegawa Y, et al. The dependence of transforming growth factor-beta-induced collagen production on autocrine factor activin A in hepatic stellate cells. Endocrinology. 2004;145(6):2753–2759. doi: 10.1210/en.2003-1663.
  • Sugiyama M, Ichida T, Sato T, et al. Expression of activin A is increased in cirrhotic and fibrotic rat livers. Gastroenterology. 1998;114(3):550–558. doi: 10.1016/s0016-5085(98)70539-6.
  • Yndestad A, Haukeland JW, Dahl TB, et al. A complex role of activin A in non-alcoholic fatty liver disease. Am J Gastroenterol. 2009;104(9):2196–2205. doi: 10.1038/ajg.2009.318.
  • Kiagiadaki F, Kampa M, Voumvouraki A, et al. Activin-A causes hepatic stellate cell activation via the induction of TNFalpha and TGFbeta in kupffer cells. Biochim Biophys Acta Mol Basis Dis. 2018;1864(3):891–899. doi: 10.1016/j.bbadis.2017.12.031.
  • Polyzos SA, Kountouras J, Anastasilakis AD, et al. Activin A and follistatin in patients with nonalcoholic fatty liver disease. Metabolism. 2016;65(10):1550–1558. doi: 10.1016/j.metabol.2016.07.009.
  • Nasr P, Ignatova S, Kechagias S, et al. Natural history of nonalcoholic fatty liver disease: a prospective follow-up study with serial biopsies. Hepatol Commun. 2018;2(2):199–210. doi: 10.1002/hep4.1134.
  • Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313–1321. doi: 10.1002/hep.20701.
  • Bedossa P, Poitou C, Veyrie N, et al. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology. 2012;56(5):1751–1759. doi: 10.1002/hep.25889.
  • Bedossa P, Consortium FP. Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. Hepatology. 2014;60(2):565–575. doi: 10.1002/hep.27173.
  • Negoita F, Blomdahl J, Wasserstrom S, et al. PNPLA3 variant M148 causes resistance to starvation-mediated lipid droplet autophagy in human hepatocytes. J Cell Biochem. 2019;120(1):343–356. doi: 10.1002/jcb.27378.
  • Grusch M, Drucker C, Peter-Vörösmarty B, et al. Deregulation of the activin/follistatin system in hepatocarcinogenesis. J Hepatol. 2006;45(5):673–680. doi: 10.1016/j.jhep.2006.06.014.
  • Wang P-W, Lin T-Y, Yang P-M, et al. Hepatic stellate cell modulates the immune microenvironment in the progression of hepatocellular carcinoma. Int J Mol Sci. 2022;23(18):10777. doi: 10.3390/ijms231810777.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.